Industry Collaboration Targets Patient-Reported Outcomes Tools In Cancer
Executive Summary
Industry efforts to collaborate on drug development issues have moved into the arena of patient-reported outcomes, with a consortium forming to improve ways patients report cancer-related fatigue
You may also be interested in...
Antibiotic Trials For COPD May Hinge On Patient-Reported Outcomes, FDA Says
Outcomes that are clinically important to patients should be the focus of clinical trials for antibiotics to treat acute bacterial exacerbation of chronic bronchitis in patients with chronic obstructive pulmonary disease, FDA recommends in a 1draft guidance released Aug. 21
Antibiotic Trials For COPD May Hinge On Patient-Reported Outcomes, FDA Says
Outcomes that are clinically important to patients should be the focus of clinical trials for antibiotics to treat acute bacterial exacerbation of chronic bronchitis in patients with chronic obstructive pulmonary disease, FDA recommends in a 1draft guidance released Aug. 21
Nephrotoxicity Biomarker Prepares For Clinic After FDA Blesses Animal Test
The firms that obtained FDA/EMEA qualification of seven nephrotoxicity biomarkers for preclinical drug testing are midway through development of a protocol to test their efficacy in a clinical trial